drugset / Trial / NCT00276276

Active Symptom Control Alone Or In Combination With Oral Topotecan In Patients With Relapsed Resistant Small Cell Lung Cancer

NCT00276276

Phase 3 Completed 141 enrolled GlaxoSmithKline
RandomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to find out if giving oral HYCAMTIN to patients with relapsed small cell lung cancer benefits them. The study will compare how long patients live when they are given therapy to make them feel better (active symptom control) to the length of time patients live when they are also receiving oral HYCAMTIN.

Timeline

Start
2000-11
Primary completion
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Topotecan Small molecule Oral